| __timestamp | Amneal Pharmaceuticals, Inc. | Amphastar Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 335989000 | 159205000 |
| Thursday, January 1, 2015 | 367054000 | 174172000 |
| Friday, January 1, 2016 | 420770000 | 150976000 |
| Sunday, January 1, 2017 | 507476000 | 149380000 |
| Monday, January 1, 2018 | 946588000 | 187681000 |
| Tuesday, January 1, 2019 | 1273376000 | 190434000 |
| Wednesday, January 1, 2020 | 1364130000 | 206506000 |
| Friday, January 1, 2021 | 1324696000 | 238029000 |
| Saturday, January 1, 2022 | 1427596000 | 250127000 |
| Sunday, January 1, 2023 | 1573042000 | 293274000 |
Infusing magic into the data realm
In the competitive landscape of pharmaceuticals, cost efficiency is paramount. From 2014 to 2023, Amneal Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc. have showcased contrasting trajectories in their cost of revenue. Amneal's cost efficiency has seen a dramatic increase, with a staggering 368% rise from 2014 to 2023. In contrast, Amphastar's cost of revenue grew by approximately 84% over the same period. This divergence highlights Amneal's aggressive expansion and operational scaling, while Amphastar maintains a more conservative growth strategy. The data reveals that by 2023, Amneal's cost of revenue was over five times that of Amphastar, underscoring the different paths these companies have taken. As the pharmaceutical industry continues to evolve, understanding these financial dynamics is crucial for investors and stakeholders alike.
Cost of Revenue Trends: Gilead Sciences, Inc. vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Zoetis Inc. and Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Incyte Corporation vs Amneal Pharmaceuticals, Inc.
Viatris Inc. vs Amneal Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Insmed Incorporated and Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Walgreens Boots Alliance, Inc. vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Jazz Pharmaceuticals plc and Amneal Pharmaceuticals, Inc.
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Amneal Pharmaceuticals, Inc.'s Expenses
Cost of Revenue: Key Insights for Telix Pharmaceuticals Limited and Amphastar Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Mesoblast Limited vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Iovance Biotherapeutics, Inc. vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and Galapagos NV